EA201891780A1 - Производные сульфонамида и содержащие их фармацевтические композиции - Google Patents

Производные сульфонамида и содержащие их фармацевтические композиции

Info

Publication number
EA201891780A1
EA201891780A1 EA201891780A EA201891780A EA201891780A1 EA 201891780 A1 EA201891780 A1 EA 201891780A1 EA 201891780 A EA201891780 A EA 201891780A EA 201891780 A EA201891780 A EA 201891780A EA 201891780 A1 EA201891780 A1 EA 201891780A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
sulphonamide
pharmaceutical compositions
compounds
integrin
Prior art date
Application number
EA201891780A
Other languages
English (en)
Other versions
EA036432B1 (ru
Inventor
Минетака Токомасу
Масацугу Ногути
Мидзуки Кавахира
Кана Ивасаки
Нобухико Хайакава
Ватару Миянага
Юки Саитоу
Юи Ямаура
Аятоси Андо
Ацуси Цурута
Мисато Ногути
Original Assignee
Эа Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эа Фарма Ко., Лтд. filed Critical Эа Фарма Ко., Лтд.
Publication of EA201891780A1 publication Critical patent/EA201891780A1/ru
Publication of EA036432B1 publication Critical patent/EA036432B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предложены соединения, обладающие ингибирующим действием на α4-интегрин. Соединения представляют собой производные сульфонамида следующей формулы (I), либо их фармацевтически приемлемые соли:где R-R, e, f, g, h, D и B означают то, что указано в описании.
EA201891780A 2016-02-05 2017-02-06 Производные сульфонамида и содержащие их фармацевтические композиции EA036432B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016021053 2016-02-05
PCT/JP2017/004278 WO2017135472A1 (ja) 2016-02-05 2017-02-06 スルホンアミド誘導体及びそれを含有する医薬組成物

Publications (2)

Publication Number Publication Date
EA201891780A1 true EA201891780A1 (ru) 2019-02-28
EA036432B1 EA036432B1 (ru) 2020-11-10

Family

ID=59500204

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891780A EA036432B1 (ru) 2016-02-05 2017-02-06 Производные сульфонамида и содержащие их фармацевтические композиции

Country Status (16)

Country Link
US (1) US10562898B2 (ru)
EP (1) EP3412660B9 (ru)
JP (1) JP6820282B2 (ru)
KR (1) KR20180104758A (ru)
CN (1) CN108699008B (ru)
AU (1) AU2017214589B2 (ru)
CA (1) CA3013433A1 (ru)
DK (1) DK3412660T3 (ru)
EA (1) EA036432B1 (ru)
ES (1) ES2856125T3 (ru)
HU (1) HUE053354T2 (ru)
MX (1) MX2018009459A (ru)
PL (1) PL3412660T3 (ru)
PT (1) PT3412660T (ru)
TW (1) TWI730042B (ru)
WO (1) WO2017135472A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024734A1 (en) 1998-10-26 2000-05-04 The Research Foundation Of State University Of New York Lipoic acid derivatives and their use in treatment of disease
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP7192139B2 (ja) 2018-10-30 2022-12-19 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリン阻害剤としてのキノリン誘導体
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
TW202330490A (zh) 2021-10-05 2023-08-01 日商Ｅａ製藥股份有限公司 化合物或其藥學上所容許之鹽的製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
CA2392566A1 (en) 1999-12-06 2001-06-14 F. Hoffmann-La Roche Ag 4-pyridinyl-n-acyl-l-phenylalanines
AU2001234741A1 (en) 2000-02-04 2001-08-14 Biogen, Inc. Integrin antagonists
PL223152B1 (pl) 2000-08-18 2016-10-31 Ajinomoto Kk Pochodne fenyloalaniny, kompozycja farmaceutyczna oraz zastosowanie tych pochodnych
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
JP4233353B2 (ja) 2002-02-27 2009-03-04 田辺三菱製薬株式会社 医薬組成物
TW200509930A (en) * 2003-06-25 2005-03-16 Elan Pharm Inc Methods and compositions for treating rheumatoid arthritis
JP4743659B2 (ja) 2003-12-22 2011-08-10 味の素株式会社 新規フェニルアラニン誘導体
CN1938283A (zh) 2004-02-10 2007-03-28 詹森药业有限公司 作为α4整联蛋白拮抗剂的哒嗪酮
CA2563432A1 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
BRPI0611285A2 (pt) 2005-05-20 2010-08-31 Elan Pharm Inc derivados de imidazolona fenilalanina
EP2842945B1 (en) * 2012-04-24 2016-10-26 EA Pharma Co., Ltd. Sulfonamide derivative and medicinal use thereof
DE102013206014A1 (de) * 2013-04-05 2014-10-09 Dürr Systems GmbH Energiewandler-System und Baugruppen hierfür
WO2015064580A1 (ja) 2013-10-29 2015-05-07 味の素株式会社 スルホンアミド誘導体及びその医薬用途

Also Published As

Publication number Publication date
TW201733991A (zh) 2017-10-01
ES2856125T3 (es) 2021-09-27
EP3412660B1 (en) 2020-11-18
PT3412660T (pt) 2021-01-13
PL3412660T3 (pl) 2021-04-19
JP6820282B2 (ja) 2021-01-27
CN108699008A (zh) 2018-10-23
EA036432B1 (ru) 2020-11-10
DK3412660T3 (da) 2020-11-30
CA3013433A1 (en) 2017-08-10
EP3412660A4 (en) 2019-07-10
MX2018009459A (es) 2018-09-21
AU2017214589B2 (en) 2020-09-03
AU2017214589A1 (en) 2018-08-16
TWI730042B (zh) 2021-06-11
JPWO2017135472A1 (ja) 2018-11-29
KR20180104758A (ko) 2018-09-21
HUE053354T2 (hu) 2021-06-28
CN108699008B (zh) 2021-10-08
WO2017135472A1 (ja) 2017-08-10
EP3412660A1 (en) 2018-12-12
US20190040059A1 (en) 2019-02-07
BR112018015855A2 (pt) 2018-12-26
EP3412660B9 (en) 2021-04-14
US10562898B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
EA201891780A1 (ru) Производные сульфонамида и содержащие их фармацевтические композиции
ECSP18082774A (es) Derivados aromáticos de sulfonamida
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
DK3986890T3 (da) Benzisoxazol-sulfonamid-derivater
EA201691302A1 (ru) Новые гетероциклические соединения
EA201891438A1 (ru) Кислотно-аддитивные соли производных пиперазина
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201690127A1 (ru) Состав на основе ингибиторов syk
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
MD3319612T2 (ro) Oxisteroli și metode de utilizare a acestora
EA201991700A1 (ru) Селективные ингибиторы jak1
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
EA202191519A1 (ru) Модуляторы trex1
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201991595A1 (ru) Активатор nrf2
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201692270A1 (ru) Производные нафтиридиндиона
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM